New Treatment for Aplastic Anemia Using Four Medicines
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a combination of four medicines (cyclosporine, eltrombopag or hetrombopag, romiplostim, and supportive care) for newly diagnosed aplastic anemia—a serious blood disorder where the bone marrow stops making enough blood cells. The goal is to help your bone marrow work better and reduce your need for blood transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Recently diagnosed with aplastic anemia confirmed by blood tests and bone marrow biopsy
- Platelet count below 30,000 per microliter of blood
- Not a candidate for stem cell transplant or ATG (a standard first-line treatment)
- Liver and kidney function no more than twice the normal limit
- Able to perform light daily activities (ECOG score 2 or better)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called enarodustat combined with an existing immune-suppressing medicine (CsA) to treat aplastic anemia—a rare blood disorder where your bone marrow doesn't make enough blood cells. The goal is to help your body produce more red blood cells without needing a bone marrow transplant.
This trial tests two different sources of donor cells for a transplant in patients with severe aplastic anemia (a condition where the bone marrow stops making enough blood cells). The study compares using cells from blood alone versus cells from both bone marrow and blood, to see which approach works better.
This trial tests if a drug called luspatercept can help people with a type of aplastic anemia that requires regular blood transfusions. It may reduce how often you need transfusions by boosting your body's own blood cell production.
This trial tests a new way to treat severe aplastic anemia by combining a stem cell transplant from a half-matched donor with special stem cells from umbilical cord blood. The goal is to help your body make healthy blood cells again.
This trial tests whether adding romiplostim (a drug that helps make platelets) to standard immunosuppressive therapy works better than standard therapy alone for people with severe aplastic anemia who have not been treated before. It aims to see if the combination can improve blood counts.
This trial tests a drug called romiplostim (Nplate) for patients whose aplastic anemia—a rare blood disorder where the bone marrow stops making enough blood cells—didn't improve after cancer treatment and hasn't responded to other medications. The drug may help your bone marrow produce more blood cells.
Hear when a new Transfusion-dependent Non-severe Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.